Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026Viking Therapeutics, Inc. misses on earnings expectations.
Viking Therapeutics Inc. (VKTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 2,129,228 | $74,906,241 | +37% | 0.15% |
| 2. | Citadel Investment Group Ken Griffin | 1,732,421 | $60,946,570 | -9% | 0.01% |
| 3. | D E Shaw D. E. Shaw | 1,718,493 | $60,456,584 | +966% | 0.03% |
| 4. | 1,435,600 | $50,504,408 | +14% | 0.01% | |
| 5. | 935,600 | $32,914,408 | -25% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $2.47 | 45,000 | $111,195.00 | 111,250 | 2022-05-02 | Filing | |
| $5.69 | 20,000 | $113,800.00 | 66,250 | 2021-06-10 | Filing | |
| $9.82 | 9,500 | $93,260.55 | 9,500 | 2018-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.09 | 1,500 | $48,133.05 | 189,891 | 2026-01-05 | Filing | |
| $34.24 | 10,300 | $352,634.92 | 191,371 | 2026-01-05 | Filing | |
| $33.38 | 13,900 | $464,020.92 | 201,671 | 2026-01-05 | Filing | |
| $32.30 | 31,961 | $1,032,180.50 | 215,571 | 2026-01-05 | Filing | |
| $35.07 | 1,600 | $56,116.96 | 409,190 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,984,487 | $351,254,252 | 0.01% | |
| 2. | 6,611,874 | $232,605,730 | 0% | |
| 3. | 6,557,766 | $230,702,223 | 0.01% | |
| 4. | 4,445,430 | $156,390,227 | 0.01% | |
| 5. | 3,076,270 | $108,223,187 | 0.01% |
News See All
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc.
10 Best US Stocks to Buy Under $50
Volatility is on the rise amid a return to tariff-fuelled market pullbacks.
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook
Viking Therapeutics grew its share prices by 11.89 percent on Wednesday to finish at $34.34 apiece as investors took heart from comments that the weight loss industry appears larger than visible, sparking...
Jim Cramer Discussed These 11 Stocks and Recent Market Rotation
Jim Cramer, the host of Mad Money, said on Thursday that the market is moving through a familiar rotation in which stocks that led gains previously are now being sold to raise cash, while names that lagged...
Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)
On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research.
Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Hedge Fund Resource Center